“Summit Therapeutics Shares Are Trading Higher After the Company Announced That It Received Marketing Authorization in China for Ivonescimab in Combination With Chemotherapy. Also, the Company Announced That It Accepted an Unsolicited Offer From an Institutional Investor to Purchase 22,222,222...